Human LRIG1 Protein

Cat. No. LRI-HM101

Description

Source	Recombinant Human LRIG1 Protein is expressed from HEK293 with His tag at the C-Terminus.
	It contains Ala35-Ser779.
Accession	Q96JA1-1
Molecular Weight	The protein has a predicted MW of 83 kDa. Due to glycosylation, the protein migrates to 85-105 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE

Formulation and Storage

Formulation	Lyophilized from 0.22μm filtered solution in 50mM MES, 150mM NaCl, 1mM EDTA (pH 5.0). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM MES, 150mM NaCl, 1mM EDTA (pH 5.0).
Storage	-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers. Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone.

Assay Data

Bis-Tris PAGE



Human LRIG1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data



Immobilized Human LRIG1, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Anti-LRIG1 Antibody, hFc Tag with the EC50 of 2.9ng/ml determined by ELISA.